Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06285318
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2023-11-27
Brief Title:
A Study of Clinical Outcomes in Patients With RelapsedRefractory Multiple Myeloma RRMM Treated With T-cell Redirectors Outside of Clinical Trials
Sponsor:
Janssen-Cilag Ltd
Organization:
Janssen-Cilag Ltd
Study Overview
Official Title:
A Retrospective Multicountry Study of Clinical Outcomes in Patients With RelapsedRefractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REALiTECTAL
Brief Summary:
The purpose of this study is to describe the use of teclistamabtalquetamab in the treatment of patients with RRMM outside of clinical trials
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None